Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients

PALO ALTO, Calif., March 21, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the out-of-pocket costs for its product portfolio for commercially insured patients is expected to be capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company’s postherpetic neuralgia pain product, ZTlido®, migraine product, ELYXYB®, and gout flare prophylaxis product, Gloperba®, which is expected to launch in the first half of 2024. Scilex has made significant investments to improve patient affordability and access to its products and continues to build on the Company’s commitment to provide non-opioid pain management products to patients.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks